This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Bladder Cancer
  • /
  • Developing Precision Medicine for Bladder Cancer

Developing Precision Medicine for Bladder Cancer

Read time: 1 mins
Published:1st Jun 2021
Author: Guercio BJ, Iyer G, Rosenberg JE.
Availability: Pay for access, or by subscription
Ref.:Hematol Oncol Clin North Am. 2021 Jun;35(3):633-653.
Developing Precision Medicine for Bladder Cancer

The hallmark of precision medicine involves tailoring the treatment to the patient and/or tumor-specific biomarkers. Candidate biomarkers in bladder cancer are abundant, but few have been validated in clinical practice. Significant obstacles to precision medicine in bladder cancer include the limited predictive value of candidate biomarkers, lack of standardization in biomarker assessment, heterogeneity in biomarker expression and function, and limited insight into the biologic factors that influence biomarker expression and predictive capacity. This review summarizes key biomarkers explored in bladder cancer and outlines innovative trial designs to approach these obstacles.

Read abstract on library site Access full article